COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Remdesivir study #11 of 16
10/20 Late treatment study
Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint)
Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository
Source   PDF   Share   Tweet
Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality.

Solh et al., 10/20/2020, retrospective, database analysis, USA, North America, preprint, 5 authors.
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 63 of 219 (28.8%), control 202 of 424 (47.6%), adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 16 studies
Please send us corrections, updates, or comments.